Agenus Inc. (AGEN) is a publicly traded Healthcare sector company. As of May 21, 2026, AGEN trades at $3.14 with a market cap of $131.59M and a P/E ratio of 1.88. AGEN moved +1.62% today. Year to date, AGEN is -2.17%; over the trailing twelve months it is -17.97%. Its 52-week range spans $1.38 to $7.34. Analyst consensus is buy with an average price target of $23.00. Rallies surfaces AGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Agenus Q1 Revenue Misses at $33.7M; Net Income $39.2M Turns Positive: Agenus reported Q1 revenue of $33.7M, up from $24.1M, but fell short of the $129.5M consensus estimate, while delivering net income of $39.2M versus a $26.4M loss last year. The company closed a $91M Zydus Lifesciences deal, boosted cash to $35M, and began global Phase 3 BATTMAN trial enrollment.
| Metric | Value |
|---|---|
| Price | $3.14 |
| Market Cap | $131.59M |
| P/E Ratio | 1.88 |
| EPS | $1.66 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.34 |
| 52-Week Low | $1.38 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $123.87M |
| Net Income | $62.49M |
| Gross Margin | 0.00% |
1 analysts cover AGEN: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $23.00.